hydroxyproline has been researched along with Cryptogenic Fibrosing Alveolitis in 26 studies
Hydroxyproline: A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.
hydroxyproline : A proline derivative that is proline substituted by at least one hydroxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pirfenidone (PFD) is the first and only clinically used antifibrotic drug for the treatment of idiopathic pulmonary fibrosis (IPF)." | 7.79 | Possible involvement of pirfenidone metabolites in the antifibrotic action of a therapy for idiopathic pulmonary fibrosis. ( Kanehira, Y; Tada, H; Togami, K, 2013) |
| "Resveratrol has a preventive potential on bleomycin-induced pulmonary fibrosis in prophylactic use; however, it was not studied in the treatment of the fibrosis." | 7.78 | Effect of resveratrol on treatment of bleomycin-induced pulmonary fibrosis in rats. ( Akgedik, R; Akgedik, S; Armutcu, F; Bozkurt, B; Karamanlı, H; Ozol, D; Uysal, S; Yıldırım, Z, 2012) |
| "Curcumin LPMPs are a promising inhalable medication for the treatment of IPF." | 5.48 | Inhalation treatment of idiopathic pulmonary fibrosis with curcumin large porous microparticles. ( Hu, Y; Jin, Y; Li, M; Zhang, M, 2018) |
| "Pirfenidone (PFD) is the first and only clinically used antifibrotic drug for the treatment of idiopathic pulmonary fibrosis (IPF)." | 3.79 | Possible involvement of pirfenidone metabolites in the antifibrotic action of a therapy for idiopathic pulmonary fibrosis. ( Kanehira, Y; Tada, H; Togami, K, 2013) |
| " Animal survival, body weight, hydroxyproline content in the lungs, lung histology, mRNA, and protein expression were studied." | 3.79 | Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2. ( Garbuzenko, OB; Ivanova, V; Minko, T; Pozharov, VP; Reimer, DC; Reuhl, KR, 2013) |
| "Resveratrol has a preventive potential on bleomycin-induced pulmonary fibrosis in prophylactic use; however, it was not studied in the treatment of the fibrosis." | 3.78 | Effect of resveratrol on treatment of bleomycin-induced pulmonary fibrosis in rats. ( Akgedik, R; Akgedik, S; Armutcu, F; Bozkurt, B; Karamanlı, H; Ozol, D; Uysal, S; Yıldırım, Z, 2012) |
| "Lung fibrosis was evaluated by histological examinations and hydroxyproline colorimetric assay." | 1.91 | Insights into Overlappings of Fibrosis and Cancer: Exploring the Tumor-related Cardinal Genes in Idiopathic Pulmonary Fibrosis. ( Assarehzadegan, MA; Bayati, P; Mojtabavi, N; Poormoghim, H; Soleimani, M; Taherian, M, 2023) |
| "Idiopathic pulmonary fibrosis is a chronic, fibrosing interstitial pneumonia that presents with various clinical courses and progression ranging from rapid to slow." | 1.62 | IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis. ( Fujitaka, K; Hamada, H; Hattori, N; Horimasu, Y; Iwamoto, H; Masuda, T; Miyamoto, S; Nakanishi, Y; Nakashima, T; Ohshimo, S; Sakamoto, S; Yamaguchi, K, 2021) |
| "Idiopathic pulmonary fibrosis is characterized by loss of lung epithelial cells and inexorable progression of fibrosis with no effective and approved treatments." | 1.51 | Distal airway stem cells ameliorate bleomycin-induced pulmonary fibrosis in mice. ( Chen, M; Dong, M; Gao, Y; Han, L; Jin, F; Li, W; Lin, H; Shi, Y; Zhou, Y; Zuo, W, 2019) |
| "Curcumin LPMPs are a promising inhalable medication for the treatment of IPF." | 1.48 | Inhalation treatment of idiopathic pulmonary fibrosis with curcumin large porous microparticles. ( Hu, Y; Jin, Y; Li, M; Zhang, M, 2018) |
| "Idiopathic pulmonary fibrosis is a progressive, fatal disease with limited treatment options." | 1.43 | Secretory leukocyte protease inhibitor gene deletion alters bleomycin-induced lung injury, but not development of pulmonary fibrosis. ( Habgood, AN; Jenkins, G; John, AE; Johnson, SR; Laurent, GJ; Porte, J; Tatler, AL; Wahl, SM, 2016) |
| "Successful recovery from lung injury requires the repair and regeneration of alveolar epithelial cells to restore the integrity of gas-exchanging regions within the lung and preserve organ function." | 1.43 | Hyaluronan and TLR4 promote surfactant-protein-C-positive alveolar progenitor cell renewal and prevent severe pulmonary fibrosis in mice. ( Chen, H; Geng, Y; Jiang, D; Kurkciyan, A; Liang, J; Liu, N; Mena, JM; Noble, PW; Stripp, BR; Xie, T; Zhang, Y, 2016) |
| "Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive interstitial lung disease with unknown etiology and undefined treatment modality." | 1.40 | CCN5 overexpression inhibits profibrotic phenotypes via the PI3K/Akt signaling pathway in lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis and in an in vivo model of lung fibrosis. ( Li, Y; Liang, C; Yang, W; Zhang, L, 2014) |
| "Rolipram (0." | 1.35 | Rolipram attenuates bleomycin A5-induced pulmonary fibrosis in rats. ( Hou, YH; Pan, JB; Zhang, GJ, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.85) | 29.6817 |
| 2010's | 19 (73.08) | 24.3611 |
| 2020's | 6 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Song, S | 1 |
| Fu, Z | 1 |
| Guan, R | 1 |
| Zhao, J | 2 |
| Yang, P | 1 |
| Li, Y | 3 |
| Yin, H | 1 |
| Lai, Y | 1 |
| Gong, G | 1 |
| Zhao, S | 1 |
| Yu, J | 1 |
| Peng, X | 1 |
| He, Y | 1 |
| Luo, Y | 1 |
| Zhong, N | 1 |
| Su, J | 1 |
| Pei, X | 1 |
| Zheng, F | 1 |
| Lin, Z | 1 |
| Han, X | 1 |
| Feng, Y | 1 |
| Tian, Z | 1 |
| Ren, D | 1 |
| Cao, K | 1 |
| Li, C | 1 |
| Taherian, M | 1 |
| Bayati, P | 1 |
| Assarehzadegan, MA | 1 |
| Soleimani, M | 1 |
| Poormoghim, H | 1 |
| Mojtabavi, N | 1 |
| Skurikhin, E | 1 |
| Madonov, P | 1 |
| Pershina, O | 1 |
| Ermakova, N | 1 |
| Pakhomova, A | 1 |
| Widera, D | 1 |
| Pan, E | 1 |
| Zhukova, M | 1 |
| Sandrikina, L | 1 |
| Artamonov, A | 1 |
| Dygai, A | 1 |
| Nakanishi, Y | 1 |
| Horimasu, Y | 1 |
| Yamaguchi, K | 1 |
| Sakamoto, S | 1 |
| Masuda, T | 1 |
| Nakashima, T | 1 |
| Miyamoto, S | 1 |
| Iwamoto, H | 1 |
| Ohshimo, S | 1 |
| Fujitaka, K | 1 |
| Hamada, H | 1 |
| Hattori, N | 1 |
| Ren, Y | 1 |
| Shi, Y | 4 |
| Chen, C | 1 |
| Chen, X | 1 |
| Lv, C | 1 |
| Hu, Y | 1 |
| Li, M | 1 |
| Zhang, M | 1 |
| Jin, Y | 1 |
| Gaugg, MT | 1 |
| Engler, A | 1 |
| Bregy, L | 1 |
| Nussbaumer-Ochsner, Y | 1 |
| Eiffert, L | 1 |
| Bruderer, T | 1 |
| Zenobi, R | 1 |
| Sinues, P | 1 |
| Kohler, M | 1 |
| Dong, M | 1 |
| Zhou, Y | 1 |
| Li, W | 1 |
| Gao, Y | 1 |
| Han, L | 1 |
| Chen, M | 1 |
| Lin, H | 1 |
| Zuo, W | 1 |
| Jin, F | 1 |
| Gochuico, BR | 1 |
| Yu, G | 1 |
| Tang, X | 1 |
| Osorio, JC | 1 |
| Fernandez, IE | 1 |
| Risquez, CF | 1 |
| Patel, AS | 1 |
| Wathelet, MG | 1 |
| Goodwin, AJ | 1 |
| Haspel, JA | 1 |
| Ryter, SW | 1 |
| Billings, EM | 1 |
| Kaminski, N | 1 |
| Morse, D | 1 |
| Rosas, IO | 1 |
| Nkyimbeng, T | 1 |
| Ruppert, C | 1 |
| Shiomi, T | 1 |
| Dahal, B | 1 |
| Lang, G | 1 |
| Seeger, W | 1 |
| Okada, Y | 1 |
| D'Armiento, J | 1 |
| Günther, A | 1 |
| Togami, K | 1 |
| Kanehira, Y | 1 |
| Tada, H | 1 |
| Zhang, L | 1 |
| Liang, C | 1 |
| Yang, W | 1 |
| Redente, EF | 1 |
| Keith, RC | 1 |
| Janssen, W | 1 |
| Henson, PM | 1 |
| Ortiz, LA | 1 |
| Downey, GP | 1 |
| Bratton, DL | 1 |
| Riches, DW | 1 |
| Parra, ER | 1 |
| Pincelli, MS | 1 |
| Teodoro, WR | 1 |
| Velosa, AP | 1 |
| Martins, V | 1 |
| Rangel, MP | 1 |
| Barbas-Filho, JV | 1 |
| Capelozzi, VL | 1 |
| Chilakapati, SR | 1 |
| Serasanambati, M | 1 |
| Vissavajjhala, P | 1 |
| Kanala, JR | 1 |
| Chilakapati, DR | 1 |
| Jiang, H | 1 |
| Zhang, J | 1 |
| Zhang, Z | 1 |
| Ren, S | 1 |
| Zhang, C | 1 |
| Wang, L | 1 |
| Song, Y | 1 |
| Li, X | 1 |
| Guo, H | 1 |
| Zhang, G | 1 |
| Habgood, AN | 1 |
| Tatler, AL | 1 |
| Porte, J | 1 |
| Wahl, SM | 1 |
| Laurent, GJ | 1 |
| John, AE | 1 |
| Johnson, SR | 1 |
| Jenkins, G | 1 |
| Liang, J | 1 |
| Zhang, Y | 1 |
| Xie, T | 1 |
| Liu, N | 1 |
| Chen, H | 1 |
| Geng, Y | 1 |
| Kurkciyan, A | 1 |
| Mena, JM | 1 |
| Stripp, BR | 1 |
| Jiang, D | 1 |
| Noble, PW | 1 |
| Westergren-Thorsson, G | 1 |
| Hedström, U | 1 |
| Nybom, A | 1 |
| Tykesson, E | 1 |
| Åhrman, E | 1 |
| Hornfelt, M | 1 |
| Maccarana, M | 1 |
| van Kuppevelt, TH | 1 |
| Dellgren, G | 1 |
| Wildt, M | 1 |
| Zhou, XH | 1 |
| Eriksson, L | 1 |
| Bjermer, L | 1 |
| Hallgren, O | 1 |
| Pan, JB | 1 |
| Hou, YH | 1 |
| Zhang, GJ | 1 |
| Nagai, T | 1 |
| Tanaka, M | 1 |
| Hasui, K | 1 |
| Shirahama, H | 1 |
| Kitajima, S | 1 |
| Yonezawa, S | 1 |
| Xu, B | 1 |
| Matsuyama, T | 1 |
| Akgedik, R | 1 |
| Akgedik, S | 1 |
| Karamanlı, H | 1 |
| Uysal, S | 1 |
| Bozkurt, B | 1 |
| Ozol, D | 1 |
| Armutcu, F | 1 |
| Yıldırım, Z | 1 |
| Ivanova, V | 1 |
| Garbuzenko, OB | 1 |
| Reuhl, KR | 1 |
| Reimer, DC | 1 |
| Pozharov, VP | 1 |
| Minko, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Exhaled Breath Analysis by Secondary Electrospray Ionization - Mass Spectrometry (SESI-MS) in Patients With Pulmonary Fibrosis[NCT02437448] | 31 participants (Actual) | Observational | 2015-06-30 | Completed | |||
| Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19[NCT04394416] | Phase 3 | 204 participants (Anticipated) | Interventional | 2020-06-02 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
26 other studies available for hydroxyproline and Cryptogenic Fibrosing Alveolitis
| Article | Year |
|---|---|
Intracellular hydroxyproline imprinting following resolution of bleomycin-induced pulmonary fibrosis.
Topics: Animals; Bleomycin; Collagen; Disease Models, Animal; Humans; Hydroxyproline; Idiopathic Pulmonary F | 2022 |
Niclosamide Ethanolamine Salt Alleviates Idiopathic Pulmonary Fibrosis by Modulating the PI3K-mTORC1 Pathway.
Topics: Animals; Bleomycin; Ethanolamine; Hydroxyproline; Idiopathic Pulmonary Fibrosis; Mechanistic Target | 2022 |
The mechanism of lung tissue YKL-40 promoting the interstitial transformation of alveolar epithelial cells and its effect on TGF-β1 level in mice with idiopathic pulmonary fibrosis.
Topics: Alveolar Epithelial Cells; Animals; Cadherins; Chitinase-3-Like Protein 1; Epithelial Cells; Epithel | 2023 |
Insights into Overlappings of Fibrosis and Cancer: Exploring the Tumor-related Cardinal Genes in Idiopathic Pulmonary Fibrosis.
Topics: Animals; Carrier Proteins; Fibrosis; Hydroxyproline; Idiopathic Pulmonary Fibrosis; Mammals; Mechani | 2023 |
Micellar Hyaluronidase and Spiperone as a Potential Treatment for Pulmonary Fibrosis.
Topics: Animals; Cell Differentiation; Collagen Type I; Hyaluronic Acid; Hyaluronoglucosaminidase; Hydroxypr | 2021 |
IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis.
Topics: Aged; Animals; Biomarkers; Bronchoalveolar Lavage Fluid; Case-Control Studies; Disease Models, Anima | 2021 |
Simple determination of L-hydroxyproline in idiopathic pulmonary fibrosis lung tissues of rats using non-extractive high-performance liquid chromatography coupled with fluorescence detection after pre-column derivatization with novel synthetic 9-acetylimi
Topics: Animals; Carbazoles; Chromatography, High Pressure Liquid; Hydroxyproline; Idiopathic Pulmonary Fibr | 2017 |
Inhalation treatment of idiopathic pulmonary fibrosis with curcumin large porous microparticles.
Topics: Administration, Inhalation; Animals; Collagen Type I; Curcumin; Drug Carriers; Hydroxyproline; Idiop | 2018 |
Molecular breath analysis supports altered amino acid metabolism in idiopathic pulmonary fibrosis.
Topics: Aged; Alanine; Amino Acids; Area Under Curve; Biomarkers; Breath Tests; Case-Control Studies; Diseas | 2019 |
Distal airway stem cells ameliorate bleomycin-induced pulmonary fibrosis in mice.
Topics: Actins; Animals; Bleomycin; Blotting, Western; Cell Differentiation; Cells, Cultured; Disease Models | 2019 |
Syndecan-2 exerts antifibrotic effects by promoting caveolin-1-mediated transforming growth factor-β receptor I internalization and inhibiting transforming growth factor-β1 signaling.
Topics: Animals; Apoptosis; Bleomycin; Bronchoalveolar Lavage; Caveolin 1; Disease Models, Animal; Gene Expr | 2013 |
Pivotal role of matrix metalloproteinase 13 in extracellular matrix turnover in idiopathic pulmonary fibrosis.
Topics: Adult; Animals; Bleomycin; Case-Control Studies; Collagen; Extracellular Matrix; Humans; Hydroxyprol | 2013 |
Possible involvement of pirfenidone metabolites in the antifibrotic action of a therapy for idiopathic pulmonary fibrosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Collagen; Fibroblasts; Humans; Hydroxyproline; I | 2013 |
CCN5 overexpression inhibits profibrotic phenotypes via the PI3K/Akt signaling pathway in lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis and in an in vivo model of lung fibrosis.
Topics: Actins; Animals; Apoptosis; Bronchoalveolar Lavage Fluid; CCN Intercellular Signaling Proteins; Cell | 2014 |
Tumor necrosis factor-α accelerates the resolution of established pulmonary fibrosis in mice by targeting profibrotic lung macrophages.
Topics: Animals; Bleomycin; Cells, Cultured; Disease Models, Animal; fas Receptor; Hydroxyproline; Idiopathi | 2014 |
Modeling pulmonary fibrosis by abnormal expression of telomerase/apoptosis/collagen V in experimental usual interstitial pneumonia.
Topics: Animals; Apoptosis; Butylated Hydroxytoluene; Cell Proliferation; Collagen Type I; Collagen Type II; | 2014 |
Amelioration of bleomycin-induced pulmonary fibrosis in a mouse model by a combination therapy of bosentan and imatinib.
Topics: Actins; Animals; Anti-Inflammatory Agents; Bleomycin; Bosentan; Catalase; Collagen Type I; Collagen | 2015 |
Effect of transplanted adipose‑derived stem cells in mice exhibiting idiopathic pulmonary fibrosis.
Topics: Adipose Tissue; Alveolar Epithelial Cells; Animals; Apoptosis; Biomarkers; Bronchoalveolar Lavage Fl | 2015 |
Role of thioredoxin nitration in bleomycin-induced pulmonary fibrosis in rats.
Topics: Animals; Bleomycin; Disease Models, Animal; Humans; Hydroxyproline; Idiopathic Pulmonary Fibrosis; L | 2016 |
Secretory leukocyte protease inhibitor gene deletion alters bleomycin-induced lung injury, but not development of pulmonary fibrosis.
Topics: Animals; Bleomycin; Collagen; Gene Deletion; Hydroxyproline; Idiopathic Pulmonary Fibrosis; Lung; Lu | 2016 |
Hyaluronan and TLR4 promote surfactant-protein-C-positive alveolar progenitor cell renewal and prevent severe pulmonary fibrosis in mice.
Topics: Alveolar Epithelial Cells; Animals; Antibiotics, Antineoplastic; Bleomycin; Cell Line; Cell Prolifer | 2016 |
Increased deposition of glycosaminoglycans and altered structure of heparan sulfate in idiopathic pulmonary fibrosis.
Topics: Adult; Aged; Case-Control Studies; Chondroitin Sulfates; Dermatan Sulfate; Disaccharides; Female; Gl | 2017 |
Rolipram attenuates bleomycin A5-induced pulmonary fibrosis in rats.
Topics: Animals; Bleomycin; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytokines; Disease Mod | 2009 |
Effect of an immunotoxin to folate receptor beta on bleomycin-induced experimental pulmonary fibrosis.
Topics: ADP Ribose Transferases; Animals; Antibodies, Monoclonal; Antigens, CD; Antigens, Differentiation, M | 2010 |
Effect of resveratrol on treatment of bleomycin-induced pulmonary fibrosis in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Bleomycin; Bronchoalveolar Lavage Fl | 2012 |
Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2.
Topics: Administration, Intravenous; Animals; Bleomycin; Body Weight; Dinoprostone; Disease Models, Animal; | 2013 |